Partnering opportunity

Eurostars: Companies and Institutions experienced in antimicrobial and resistance mechanisms sought to develop multifunctional biodegradable nanocapsules against bacterial diseases.


Spanish SME experienced in the development and manufacturing of biodegradable polyurethane micro and nanocapsules is preparing a Eurostars proposal. The aim is to develop multifunctional biodegradable nanocapsules against bacterial diseases. Research partners with a deep understanding of antimicrobial drugs and their resistance mechanisms are sought for a research cooperation to perform the in vitro and in vivo pre-clinical validation.

Partner sought

The Spanish company as a consortium leader seeks research agreements with hospitals groups, research entities or biotech and/or pharmaceutical enterprises which are also interested in this medical field. The SME offers all of its know-how and infrastructure on the synthesis of polyurethane nanocapsules and its physical and chemical characterization and evaluation, and the partners should perform the in vitro and in vivo pre-clinical tests. Specifically, the SME is looking for partners with experience in: - In vitro tests to verify the drug selectivity and delivery to the chosen bacteria, the nanocapsules efficiency and the interaction with biofilms. - In vivo assays to test the biodistribution and efficacy.


Current medicine is very focused on the development of new therapies against multi-drug resistant (MDR) bacterial infections. The World Health Organisation (WHO) expects that in 2050 infectious diseases caused by deadly bacteria will be the principal cause of mortality in Europe. Spanish SME focused on the development of biodegradable polyurethane micro and nanocapsules for industrial, personal care and pharmaceuticals sectors specializes in the synthesis of nanopolymeric entities to selectively deliver chemical or therapeutic entities. After more than 10 years of collaborative research, the company has introduced a novel technological platform in the field of Drug Delivery Systems (DDS). This innovative technology could be very conveniently implemented in bacterial infections therapy. It is able to create authentic all-in-one nanosystems with biodegradability, targeting, penetrating and multi drug encapsulation properties. With this multifunctional DDS, it could be possible to enhance antibacterial drugs pharmacokinetics and efficacy in intravenous, inhalation, oral or topic administration. Similarly, it would be possible to reduce the therapeutic concentration of the drug, thus lowering its side effects. The SME wants to develop nanoencapsulated systems using well-known antimicrobial-drugs, with difficulties to overcome adaptive resistance in one of the deathliest opportunistic pathogen: Pseudomonas Aeruginosa. Specially, carbapenem-resistant Pseudomonas Aeruginosa has been raised at critical level in WHO’s rank for bacterial infections for which are needed novel antibiotic therapies. Pseudomonas Aeruginosa is a Gram-negative bacterium which commonly causes several nosocomial and life-threatening infections in patients with cystic fibrosis, burn wounds and pulmonary infections. This is a major cause of hospital-acquired infections in patients. In this context, nanoencapsulation could provide solutions to overcome some barriers in the efficacy of antimicrobial-drugs. Based on the company’s previous experience with biodegradable polyurethane/polyurea nanocapsules, they can contribute to avoid most of the anti-microbial resistance mechanisms developed by Pseudomonas Aeruginosa. Once encapsulated, the antimicrobial-drug would not be affected by bacterial-released enzymes that would degrade or restrain it. Moreover, external media close to the bacterial cells neither would interact with the drug. This fact allows us to put unstable antimicrobial-drugs in direct contact with the active infection bacteria. Additionally, for combination therapies treating a broader spectrum of bacterial infections, it is possible to co-encapsulate two or more drugs (hydrophobic-hydrophobic, hydrophilic-hydrophilic or hydrophobic-hydrophilic drugs combination). Through nanocapsule shell functionalization with biofilm-targeted and/or biofilm-penetrating motifs, nanocapsules could penetrate through biofilms secretions, thus driving drugs onto inaccessible bacterial colonies. The Spanish company is willing to lead a powerful consortium based on innovative encapsulated antibiotic drugs that can potentially disrupt the way we treat infections. Thus medical and biological partners with a deep understanding of antimicrobial drugs and their resistance mechanisms to perform advanced preclinical assays are sought. The project will encompass from lab developing of nanoparticles to testing them in preclinical analysis in vitro as well as in vivo. The outcome of the project would be to patent the product, create a spin-off and obtain funding to perform clinical phases 2 years after the project finalization. Partners who want to be part of this collaboration must come from the eligible countries considered in Eurostars’ bases and they have to check the finance method with their National Project Coordinator. Deadline of the call: 12th September 2019 Deadline for EOI: 31st May 2019

Advantages and innovations

Not available

Development stage

Proposal under development

Intellectual Property Rights (IPR)

Not available

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company